[EXAS] Exact Sciences Corporation


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Commercial Physical & Biological Resarch

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 14.17 Change: 0.79 (5.9%)
Ext. hours: Change: 0 (0%)

chart EXAS

Refresh chart

Strongest Trends Summary For EXAS

EXAS is in the medium-term down -27% below S&P in 1 month. In the long-term up 79% above S&P in 2 years and up 837% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Exact Sciences Corporation, a molecular diagnostics company, focuses on developing diagnostic screening products for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company?s stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with Mayo Clinic for developing tests to detect other gastro-intestinal cancers, primarily esophageal and pancreatic cance

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-42.95% ROE-46.37% ROI-45.3%
Current Ratio17.69 Quick Ratio Long Term Debt/Equity0.01 Debt Ratio0.06
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities290 K Cash From Investing Activities16.76 M Cash From Operating Activities-34.5 M Gross Profit3.02 M
Net Profit-39.07 M Operating Profit-39.37 M Total Assets253.02 M Total Current Assets223.26 M
Total Current Liabilities18.73 M Total Debt4.83 M Total Liabilities28.18 M Total Revenue8.12 M
Technical Data
High 52 week120.31 Low 52 week48.29 Last close118.29 Last change-1.33%
RSI54 Average true range5.72 Beta0.78 Volume1.89 M
Simple moving average 20 days2.03% Simple moving average 50 days3.72% Simple moving average 200 days30.44%
Performance Data
Performance Week2.8% Performance Month1.83% Performance Quart28.05% Performance Half33.34%
Performance Year136.58% Performance Year-to-date87.46% Volatility daily2.14% Volatility weekly4.79%
Volatility monthly9.81% Volatility yearly33.97% Relative Volume250.33% Average Volume1.71 M
New High New Low


2019-10-16 19:10:34 | Spiros Segalas' Top 5 Buys in the 3rd Quarter

2019-10-14 06:00:00 | Exact Sciences And Mayo Clinic Initiate 150,000 Patient, 7-Year Study To Evaluate Real-World Impact Of Cologuard®

2019-10-11 12:53:04 | Emergent's Chikungunya Vaccine Candidate Gets EMA's PRIME Tag

2019-10-11 12:40:04 | Seattle Genetics Begins Phase III Study on Tucatinib Combo

2019-10-11 11:08:36 | Do Hedge Funds Love EXACT Sciences Corporation EXAS?

2019-10-11 07:24:21 | What Did Exact Sciences Corporation's NASDAQ:EXAS CEO Take Home Last Year?

2019-10-10 11:17:03 | bluebird Inks Genome Editing Research Deal With Novo Nordisk

2019-10-10 11:15:03 | Seattle Genetics Up More Than 20% in 3 Months: Here's Why

2019-10-08 09:30:01 | Has Exact Sciences EXAS Outpaced Other Medical Stocks This Year?

2019-10-08 06:00:00 | Exact Sciences schedules third-quarter 2019 earnings call

2019-10-04 22:09:08 | Inside Genomic Health's $2.8B deal: A false start, rejections and a mysterious last-minute bidder

2019-10-03 12:46:25 | Exact Sciences continues down strong growth path

2019-09-26 10:51:17 | 3 Strong Buy Mid-Cap Stocks with High Upside

2019-09-25 09:18:01 | Exact Sciences Corporation Enters Oversold Territory

2019-09-24 11:19:00 | Exact Sciences: Finding the Exact Price to Buy the Stock

2019-09-24 11:18:39 | Cramer Weighs In On PayPal, NextEra And More

2019-09-24 09:10:01 | Exact Sciences Gets FDA Nod for Label Expansion of Cologuard

2019-09-23 16:15:16 | How A New Approval Could Help This Biotech Stock Add $3 Billion In Sales

2019-09-23 15:46:00 | PreMarket Prep Recap: Fitbit, Exact Sciences Headlines; US Steel Downgrade 'A Bit Late To The Party'

2019-09-23 13:06:13 | Exact Sciences gains $3B market opportunity as FDA approves Cologuard for 45 and older

2019-09-23 10:11:00 | Exact Sciences Stock Takes Off as FDA Approves Colon-Cancer Test for Younger People

2019-09-23 06:23:00 | Exact Sciences Lifted to Buy at Benchmark on Wider Cologuard-Use Approval

2019-09-23 05:45:00 | Cologuard® Gains FDA Approval For Use In Younger Americans, Ages 45 To 49

2019-09-20 10:49:02 | Zacks Value Trader Highlights: Exact Sciences, Edwards Lifesciences, Bristol Myers-Squibb, Occidental Petroleum and Exxon Mobil

2019-09-19 11:05:03 | Stock Investors: Do You Need a Late Cycle Plan?

2019-09-19 08:35:00 | Exact Sciences Named One of the 2019 Best Workplaces for Women by Great Place to Work® and FORTUNE

2019-09-10 06:00:00 | Cologuard® Helps More People Get Screened In A Cost-Effective Way

2019-09-05 10:41:54 | Is Exact Sciences NASDAQ:EXAS Weighed On By Its Debt Load?

2019-08-30 09:15:00 | Exact Sciences to participate in September investor conference

2019-08-28 10:38:02 | The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health

2019-08-27 09:24:01 | 3 Cancer Treatment Stocks to Enrich Your Portfolio

2019-08-20 17:17:32 | Third in wave of Bay Area biotech IPOs eyes $100M windfall after 26 years in business

2019-08-16 13:10:00 | A Breach of Trust? Here's Why the FDA's Taking Aim at Novartis' AveXis

2019-08-08 13:03:43 | 10 Stocks That Can Profit as Global Turmoil Escalates

2019-08-07 10:05:00 | Genomic Health's Second Quarter Was So Great It Got the Company Acquired

2019-08-05 16:20:50 | Here's Why Genetic Testing Stocks Rose as Much as 25.4% in July

2019-08-02 17:18:00 | GENOMIC HEALTH INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Genomic Health, Inc. - GHDX

2019-08-02 06:00:00 | Exact Sciences to participate in August investor conference

2019-08-01 19:20:48 | Acquisition Boosts Exact Sciences' Role in Cancer Diagnostics

2019-07-31 21:15:06 | Exact Sciences Corp EXAS CFO Jeffrey Thomas Elliott Sold $1 million of Shares

2019-07-31 09:42:03 | Pioneering cancer test maker's execs could grab millions in $3 billion buyout

2019-07-31 08:50:00 | Short Seller Left Goes Long on Invitae With $100 Target

2019-07-31 08:26:43 | A Look At The Fair Value Of Exact Sciences Corporation NASDAQ:EXAS

2019-07-30 17:24:13 | Exact Sciences Corp EXAS Q2 2019 Earnings Call Transcript

2019-07-30 16:55:55 | Why Exact Science Made the $2.8 Billion Deal for Genomic

2019-07-30 07:27:00 | Here's Why Exact Sciences Stock Snapped Right Back Into Place

2019-07-30 06:17:00 | Exact Sciences Is Poised to Test New Highs on the Charts

2019-07-29 20:00:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates Genomic Health, Inc.

2019-07-29 16:21:17 | What to Know about the Exact Sciences–Genomic Health Deal

2019-07-29 16:11:59 | Merger Fever Runs Hot In Pharma: Viagra, Epipen Sellers Announce Matchup